Nasal distribution of budesonide inhaled via a powder inhaler.
The distribution pattern of budesonide in the nasal passages and lungs was investigated in 10 healthy subjects after nasal inhalation. The subjects inhaled drug powder, radiolabelled with 99mTc, at maximum flow rate (46.3 +/- 6.8 l/min) and at 29.9 +/- 2.5 l/min via Turbuhaler. At both flows, the majority of the dose was deposited in the anterior part of the nasal cavity on a single, rather localized area, but some particles also penetrated more posteriorly into the main nasal passages and to the lungs. At maximum flow rate the nasal deposition was 65.2% (range 39.5-84.1%) and the lung deposition 4.7% (range 1.4-9.3%) of the metered dose, and at 30 l/min, the nasal deposition was 67.6% (range 49.7-81.6%) and the lung deposition was 4.2% (range 1.7-7.9%). A large fraction of the metered dose was deposited in the nasal adaptor of the inhaler during the administration (mean values 29 and 28%, for the two inhalation flows). Of the dose actually reaching the subject, 91 and 93% (mean values) was deposited in the nose. There were no statistically significant differences in distribution pattern between the two inhalation flows.
Thorsson
L
L
Astra Draco AB, Lund, Sweden.
Newman
S P
SP
Weisz
A
A
Trofast
E
E
Morén
F
F
D000280:Administration, Inhalation; D000328:Adult; D000336:Aerosols; D019819:Budesonide; D005260:Female; D006801:Humans; D008168:Lung / Q000378:metabolism*; D008297:Male; D009296:Nasal Cavity / Q000378:metabolism*; D011208:Powders; D011282:Pregnenediones / Q000008:administration & dosage / Q000493:pharmacokinetics*; D011849:Radioactive Tracers; D013667:Technetium; D014018:Tissue Distribution
D000336:Aerosols; D011208:Powders; D011282:Pregnenediones; D011849:Radioactive Tracers; D019819:Budesonide; D013667:Technetium